The U.S. biopharmaceutical market is no longer operating under a single dominant economic model, according to industry analyst Bill Roth.
Writing in the final instalment of his Great Repricing series, Roth argues that the assumptions manufacturers have relied on for decades are fundamentally changing.
Commercial insurance remains an important channel, but its high wholesale acquisition cost and high-rebate structure is under increasing pressure from multiple directions.
Government payers have evolved well beyond being just another segment, and now function as the industry’s largest price-setting force across the market.
Cash has re-emerged as a legitimate commercialization channel, no longer reserved only for uninsured patients or products approaching loss of exclusivity.
Roth notes that the implication of these shifts is bigger than gross-to-net compression, which was his original focus when he set out to write the series.
Medicare and direct cash channels are actively reshaping how companies think about launches, WAC cuts, and broader access strategies across a product’s commercial life.
For most of Roth’s career, pharmacy benefit products launched with high WACs and sufficient rebate flexibility to secure commercial access, a model that is now under strain.
Rather than predicting a single new pricing model to replace the old one, Roth instead challenges seven core assumptions that have guided pharmaceutical commercialization for years.
His conclusion is that manufacturers and the wider industry must now rethink how they price, launch, grow, and manage products across their full life cycles.
The series, fact-checked by Yasmeen Qahwash, reflects what Roth describes as a broad structural shift rather than simply another round of payer disruption.
What has changed is not just the mechanics of rebates or formulary access, but the foundational logic that once made those mechanics predictable and reliable for commercial teams.
As government price-setting power expands and cash channels gain credibility, the old playbook for pharmaceutical commercialization faces its most serious challenge in a generation.